Physician profile
Timothy A Shown
NPI 1811953177
$13,676.53
in general payments reported to CMS, 2019-2025
55 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,048 · 2020: $1,660 · 2021: $2,132 · 2022: $1,967 · 2023: $1,856 · 2024: $2,084 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,656 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,655.84 |
| Education | $213.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,454.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,509.00 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,324.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,059.94 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $735.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $716.02 | 2019-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $641.59 | 2019-2025 | Xifaxan |
| Pfizer INC. | $628.37 | 2019-2025 | |
| Astellas Pharma US INC | $397.91 | 2020-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $397.01 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.55 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $346.77 | 2019-2022 | |
| Abbott Laboratories | $306.11 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $205.32 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $170.63 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Shown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.